CROI 2026: HIV Research Breakthroughs & Challenges

The 33rd Conference on Retroviruses and Opportunistic Infections (CROI) 2026, held in Denver, Colorado from February 22-25, showcased a wealth of new research and discussion surrounding HIV and related conditions. Presentations at CROI 2026 highlighted both significant advancements in treatment and ongoing challenges in prevention and care, particularly concerning co-morbidities and access to innovative therapies.

Advances in HIV Treatment and Long-Acting ART

Several studies presented at the conference focused on optimizing HIV treatment strategies. Researchers from MGH (Massachusetts General Hospital) presented data on the clinical and cost impact of long-acting antiretroviral therapy (ART) in South African youth with HIV. This modeling analysis suggests potential benefits of transitioning to these less frequent dosing regimens, though further research is needed to fully assess long-term outcomes and cost-effectiveness. Xinwen Xu of MGH led this work. Long-acting ART, which involves injections administered less frequently than daily oral medication, aims to improve adherence and quality of life for people living with HIV.

Another study, led by Suzanne McCluskey at MGH, investigated the validity of point-of-care urine Tenofovir testing to differentiate between viral suppression and viremia – the presence of the virus in the bloodstream – in individuals on Tenofovir disoproxil fumarate (TDF). Accurate and rapid viral load monitoring is crucial for effective HIV management, and point-of-care tests could offer a valuable tool, particularly in resource-limited settings.

Addressing Co-morbidities: Hepatitis B, Obesity, and Glucose Metabolism

CROI 2026 as well underscored the importance of addressing co-morbidities in people living with HIV. Amir Mohareb, also from MGH, presented a modeling analysis examining the impact of HIV PrEP (pre-exposure prophylaxis) on female sex workers with Hepatitis B in Côte d’Ivoire. This research highlights the complex interplay between HIV prevention strategies and other infectious diseases.

Itai Magodoro of MGH presented findings on glucose and insulin metabolism in middle-aged women with both HIV and obesity in South Africa. This study points to the increased risk of metabolic complications in this population, emphasizing the need for integrated care that addresses both HIV and related health conditions. Understanding these metabolic changes is vital for preventing cardiovascular disease and diabetes, which are increasingly prevalent among people living with HIV.

Innovative Approaches to Prevention and Stigma Reduction

Prevention efforts were also a key focus at CROI 2026. Aima A. Ahonkhai from MGH shared results from a study evaluating the feasibility, uptake, and early outcomes of the “Cutting Out Stigma” barbershop HIV intervention. This innovative approach aims to reach men who may not typically engage with traditional healthcare services, leveraging trusted community spaces to promote HIV testing and prevention. Reducing stigma surrounding HIV remains a critical challenge, and community-based interventions like this offer promising avenues for reaching underserved populations.

The Long-Term Impact of Antiretroviral Therapy

Researchers also examined the long-term benefits of antiretroviral therapy. Kevin Kyu-young Chi of MGH presented data demonstrating the substantial survival benefits of ART for people living with HIV in the US, quantifying these benefits as “Twenty-Three Million Years of Life.” This underscores the transformative impact of ART on the HIV epidemic and the importance of continued access to treatment.

Understanding the HIV Reservoir and Immune Response

Basic science research presented at CROI 2026 explored the complexities of the HIV reservoir and the immune response. Fernando Senjobe from the University of Miami presented findings on markedly reduced mutability of networked epitopes, which promotes CTL (cytotoxic T lymphocyte) clearance of the latent HIV reservoir. This research offers insights into potential strategies for achieving a functional cure for HIV, by enhancing the body’s ability to eliminate the virus even when it remains hidden in reservoirs.

Partner Notification and STI Prevention

Ingrid Bassett of MGH investigated preferences for an electronic partner notification system for sexually transmitted infections (STIs). Effective partner notification is crucial for controlling the spread of STIs, and understanding preferences for different notification methods can inform the development of more effective public health interventions.

Featured Speakers and Conference Themes

The conference featured prominent speakers including Sharon Lewin of the University of Melbourne, Peter Staley of PrEP4All, and Linda-Gail Bekker of the University of Cape Town. CROI 2026’s opening session and plenary speakers addressed critical themes in HIV research, from basic science discoveries to implementation science and policy considerations. Peter Staley’s presentation, drawing from his experience transitioning from Wall Street to activism with ACT UP, was highlighted in a new podcast episode available through the conference website. (CROI Conference)

What Comes Next: Ongoing Research and Implementation

The research presented at CROI 2026 will inform ongoing efforts to improve HIV prevention, treatment, and care. Many of the studies highlighted the need for further research to address remaining knowledge gaps and refine interventions. Specifically, continued investigation into long-acting ART, strategies for managing co-morbidities, and innovative prevention approaches will be crucial. The Harvard University HIV research community is actively fostering engagement and collaborative research among investigators, as evidenced by the digital program booklet made available prior to the conference. (Harvard CFAR)

Public health agencies will continue to monitor the evolving HIV epidemic and update guidance based on new evidence. Individuals at risk for HIV should consult with a qualified healthcare provider to discuss appropriate prevention strategies, including PrEP. People living with HIV should adhere to their treatment regimens and seek regular medical care to manage their health and prevent transmission.